Home/Pipeline/IB-T101

IB-T101

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Inceptor Bio

About Inceptor Bio

Inceptor Bio is a private, clinical-stage biotech targeting the significant unmet need in solid tumor oncology with its innovative OUTLAST™ cell therapy platform. The company's technology conditions T cells during manufacturing to enhance their persistence, metabolic fitness, and resistance to exhaustion, aiming to achieve durable responses where current CAR-T therapies have struggled. With a lead program, IB-T101, advancing in the clinic and a seasoned leadership team with experience in cell therapy and company building, Inceptor is positioning itself as a key player in the next wave of cell therapies for solid cancers.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed